NasdaqGS:MRNABiotechs
Moderna (MRNA) Valuation Check After Global Settlement On Lipid Nanoparticle Patent Disputes
Moderna (MRNA) is back in focus after agreeing to a global settlement of up to US$2.25b with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle patents tied to its COVID-19 and RSV vaccines.
See our latest analysis for Moderna.
That settlement headlines a sharp shift in sentiment, with a 90 day share price return of 94.33% and year to date gain of 74.43% contrasting with a 3 year total shareholder return loss of 60.81%. This suggests that recent momentum is rebuilding after a...